BasuS, YudkinJS, KehlenbrinkS, et al.Estimation of global insulin use for type 2 diabetes, 2018-30: A microsimulation analysis. Lancet Diabetes Endocrinol, 2019; 7(1):25–33.
BattelinoT, AlexanderCM, AmielSA, et al.Continuous glucose monitoring and metrics for clinical trials: An international consensus statement. Lancet Diabetes Endocrinol, 2023; 11(1):42–57; doi: 10.1016/S2213-8587(22)00319-9
5.
GargSK. Past, present, and future of continuous glucose monitors. Diabetes Technol Ther, 2023; 25(S3):S1–S4; doi: 10.1089/dia.2023.0041
6.
GargS, KipnesMS, CastorinoK, et al.Accuracy and safety of Dexcom G7 continuous glucose monitoring in adults with diabetes. Diabetes Technol Ther, 2022; 24(6):373–380; doi: 10.1089/dia.2022.0011
7.
BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 2019; 42(8):1593–1603.
8.
HankoskyER, SchapiroD, GunnKB, et al.Gaps remain for achieving HbA1c targets for people with type 1 or type 2 diabetes using insulin: Results from NHANES 2009-2020. Diabetes Ther, 2023; 14(6):967–975; doi: 10.1007/s13300-023-01399-0
9.
NathanDM, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care, 2014; 37(1):9–16.
10.
RiddleMC, GersteinHC, HomePD. Lingering effects of hyperglycemia in recently diagnosed diabetes during long-term follow-up of the DCCT/EDIC and UKPDS cohorts: More evidence that early control matters. Diabetes Care, 2021; 44(10):2212–2215.
11.
HolmanRR, PaulSK, BethelA, et al.10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359(15):1577–1589; doi: 10.1056/NEJMoa0806470
12.
BoyeKS, BaeJP, ThieuVT, LageMJ. An economic evaluation of the relationship between glycemic control and total healthcare costs for adults with type 2 diabetes: Retrospective cohort study. Diabetes Ther, 2024; 15(2):395–407; doi: 10.1007/s13300-023-01507-0
13.
MoraT, Rodríguez-SánchezB. Diabetes diagnosis based on glucose control levels and time until diagnosis: A regression discontinuity approach to assess the effect on direct healthcare costs. Health Econ Rev, 2025; 15(1):26; doi: 10.1186/s13561-025-00613-y
14.
RosenfeldL. Insulin: Discovery and controversy. Clin Chem, 2002; 48(12):2270–2288.
15.
BuseJB, DaviesMJ, FrierBM, Philis-TsimikasA. 100 years on: The impact of the discovery of insulin on clinical outcomes. BMJ Open Diabetes Res Care, 2021; 9(1):e002373; doi: 10.1136/bmjdrc-2021-002373
16.
JohnsonIS. Human insulin from recombinant DNA technology. Science, 1983; 219(4585):632–637; doi: 10.1126/science.6337396
17.
MarkussenJ, DamgaardU, PingelM, et al.Human insulin (Novo): Chemistry and characteristics. Diabetes Care, 1983; 6(Suppl 1):4–8.
18.
PampanelliS, TorloneE, IalliC, et al.Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care, 1995; 18(11):1452–1459; doi: 10.2337/diacare.18.11.1452
19.
HeiseT, Stender-PetersenK, HövelmannU, et al.Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet, 2017; 56(6):649–660.
20.
DuttaD, MohindraR, MahajanK, SharmaM. Performance of fast-acting aspart insulin as compared to aspart insulin in insulin pump for managing type 1 diabetes mellitus: A meta-analysis. Diabetes Metab J, 2023; 47(1):72–81; doi: 10.4093/dmj.2022.0035
21.
HomePD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab, 2012 Sep;14(9):780–788; doi: 10.1111/j.1463-1326.2012.01580.x
22.
SanliogluAD, AltunbasHA, BalciMK, et al.Clinical utility of insulin and insulin analogs. Islets, 2013; 5(2):67–78; doi: 10.4161/isl.24590
23.
HeiseT, MeneghiniLF. Insulin stacking versus therapeutic accumulation: Understanding the differences. Endocr Pract, 2014; 20(1):75–83; doi: 10.4158/EP13090.RA
24.
SlatteryD, AmielSA, ChoudharyP. Optimal prandial timing of bolus insulin in diabetes management: A review. Diabet Med, 2018; 35(3):306–316.
25.
WongEY, KroonL. Ultra-Rapid-Acting insulins: How fast is really needed? Clin Diabetes, 2021; 39(4):415–423; doi: 10.2337/cd20-0119
26.
FamullaS, HövelmannU, FischeA, et al.Insulin injection Into Lipohypertrophic tissue: Blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care, 2016; 39(9):1486–1492.
27.
HirschIB, KhakpourD, JosephJ, et al.The DERMIS study: Methodologies, results, and implications for the future. J Diabetes Sci Technol, 2024:19322968241298005; doi: 10.1177/19322968241298005
28.
PeyrotM, RubinRR, LauritzenT, et al.On behalf of the INTERNATIONAL DAWN Advisory Panel. Psychosocial problems and barriers to improved diabetes management: Results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med, 2005; 22(10):1379–1385.
29.
HoweCJ, RatcliffeSJ, TuttleA, et al.Needle anxiety in children with type 1 diabetes and their mothers. MCN Am J Matern Child Nurs, 2011; 36(1):25–31; doi: 10.1097/NMC.0b013e3181fc6093
30.
AschnerP, GagliardinoJJ, IlkovaH, et al.High prevalence of depressive symptoms in patients with type 1 and type 2 diabetes in developing countries: Results from the international diabetes management practices study. Diabetes Care, 2021; 44(5):1100–1107; doi: 10.2337/dc20-2003
31.
FisherL, GlasgowRE, StryckerLA. The relationship between diabetes distress and clinical depression with glycemic control among patients with type 2 diabetes. Diabetes Care, 2010; 33(5):1034–1036.
32.
HeinemannL, ParkinCG. Rethinking the viability and utility of inhaled insulin in clinical practice. J Diabetes Res, 2018; 2018:4568903; doi: 10.1155/2018/4568903
33.
RosenstockJ, FrancoD, KorpachevV, et al.; Affinity 2 Study Group. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care, 2015; 38(12):2274–2281; doi: 10.2337/dc15-0629
34.
BodeBW, McGillJB, LorberDL, et al.; Affinity 1 Study Group. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: A randomized 24-week trial. Diabetes Care, 2015; 38(12):2266–2273; doi: 10.2337/dc15-0075
35.
SkylerJ. Thirty years of developing inhaled insulin. Diabetes Technol Ther, 2026; 28(Suppl 1):6S–7S; doi: 10.1177/15209156251396116
36.
EdelmanSV, BlevinsT, ParkinCG, HirschIB. Dosing Afrezza: It’s not that complicated. Diabetes Technol Ther, 2026; 28(Suppl 1):8S–13S; doi: 10.1177/15209156251403580
37.
HirschIB, ParkinCG. Current unmet needs in diabetes management. Diabetes Technol Ther, 2026; 28(Suppl 1):14S–18S; doi: 10.1177/15209156251396121
38.
McGillJB, PetersA, BuseJB, et al.Comprehensive pulmonary safety review of inhaled Technosphere® insulin in patients with diabetes mellitus. Clin Drug Investig, 2020; 40(10):973–983; doi: 10.1007/s40261-020-00958-8
39.
BeckRW, BaileyRJ, AkturkHK, et al.; INHALE-3 Study Group. A 13-Week single-arm evaluation of inhaled technosphere insulin plus insulin degludec for adults with type 1 diabetes. Diabetes Technol Ther, 2025; 27(3):161–169; doi: 10.1089/dia.2024.0581
40.
BeckRW, BaileyRJ, KleinKR, et al.; INHALE-3 Study Group. Inhaled Technosphere insulin plus insulin Degludec for adults with type 1 diabetes: The INHALE-3 extension study. Diabetes Technol Ther, 2025; 27(3):170–178; doi: 10.1089/dia.2024.0582
41.
HallerMJ, JonesMC, BhavsarS, KaisermanKB. Time-Action profile of Technosphere insulin in children with type 1 diabetes. Diabetes Ther, 2023; 14(3):611–617; doi: 10.1007/s13300-023-01368-7
42.
KaisermanKB, ChristiansenM, BhavsarS, et al.Reduction in postprandial peak glucose with increased technosphere insulin dosage. J Diabetes Sci Technol, 2024; 18(2):397–401; doi: 10.1177/19322968221110622
43.
McGillJ, MayerOH. Pulmonary safety ten years after FDA approval. Diabetes Technol Ther, 2026; 28(Suppl 1):19S–25S; doi: 10.1177/15209156251396118
44.
CowartK, EverichH, FloresF, et al.Real-world incidence of lung malignancy and chronic obstructive pulmonary disease with inhaled insulin in people with diabetes. Diabetes Technol Ther, 2026; 28(3):201–205; doi: 10.1177/15209156251387102
45.
BeckRW, GargSK, HirschIB. Safety of Inhaled Insulin in Adults with Diabetes. Diabetes Technol Ther, 2026; 28(3):191–192; doi: 10.1177/15209156251390830
46.
LevyC, SeaquistE. Impact of inhaled insulin therapy on hypoglycemia. Diabetes Technol Ther, 2026; 28(Suppl 1):26S–30S; doi: 10.1177/15209156251381294
47.
RiddellMC, ParkinCG, TurnerLV, AkturkHK. Potential applications of inhaled insulin in DKA prevention and during exercise. Diabetes Technol Ther, 2026; 28(Suppl 1):31S–37S; doi: 10.1177/15209156251408036
48.
SeniorP, HramiakI. Fast-Acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: A Canadian Perspective. Can J Diabetes, 2019; 43(7):515–523; doi: 10.1016/j.jcjd.2019.01.004
49.
LeahyJJL, AleppoG, FonsecaVA, et al.Optimizing postprandial glucose management in adults with insulin-requiring diabetes: Report and recommendations. J Endocr Soc, 2019; 3(10):1942–1957; doi: 10.1210/js.2019-00222
50.
CengizE, BeckRW. Use of inhaled insulin with AID systems. Diabetes Technol Ther, 2026; 28(Suppl 1):38S–42S; doi: 10.1177/15209156251407710
51.
RickertMC, BarbourLA, BodeBW, et al.Inhaled insulin in pregnancy: A case series supporting feasibility and clinical potential for pregnant people with diabetes. Pregnancy, 2025; 1(5):e70065; doi: 10.1002/pmf2.70065
52.
LaffelLM, ValentA. Potential role of inhaled insulin in the management of gestational diabetes mellitus and pediatric type 1 diabetes. Diabetes Technol Ther, 2026; 28(Suppl 1) :43S–54S; doi: 10.1177/15209156251403591
53.
HirschIB, BlevinsT, ValentA, RiddellMC. Case reports: Practical use of pulmonary inhaled insulin. Diabetes Technol Ther, 2026; 28(Suppl 1):55S–63S; doi: 10.1177/15209156251412813
54.
HoodK, PolonskyW. The potential of inhaled insulin therapy in overcoming treatment barriers in people with insulin-treated diabetes. Diabetes Technol Ther, 2026; 28(Suppl 1):64S–69S; doi: 10.1177/15209156251403584
